Holen Sie sich die Stockscreener-App
134.00
0.04%
0.05
Handel nachbörslich:
134.29
0.29
+0.22%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$133.95
Offen:
$133.265
24-Stunden-Volumen:
5.99M
Relative Volume:
0.89
Marktkapitalisierung:
$227.71B
Einnahmen:
$42.34B
Nettoeinkommen (Verlust:
$13.50B
KGV:
17.38
EPS:
7.71
Netto-Cashflow:
$6.66B
1W Leistung:
+2.38%
1M Leistung:
+8.11%
6M Leistung:
+14.93%
1J Leistung:
+27.69%
1-Tages-Spanne:
$133.08
$135.22
1-Wochen-Bereich:
$130.70
$136.80
52-Wochen-Spanne:
$99.71
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Vergleichen Sie ABT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
134.00 | 227.71B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.29 | 152.66B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.46 | 142.93B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.62 | 107.17B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
74.63 | 44.04B | 5.54B | 4.18B | 623.10M | 7.00 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Top Stock Reports for NVIDIA, Abbott Laboratories & Linde - Yahoo Finance
Tissue Diagnostics Market to Reach $12.4 Billion by 2029, Growing at 7.0% CAGR - GlobeNewswire Inc.
Abbott Labs Secures Dismissal of Diabetes Supply Fraud Claims - Bloomberg Law News
Reflecting On Medical Devices & SuppliesDiversified Stocks’ Q1 Earnings: Abbott Laboratories (NYSE:ABT) - Yahoo Finance
Abbott Outpaces Peers Defying Tariff Woes: Is ABT Stock a Smart Buy? - Yahoo Finance
Abbott Laboratories (ABT) Continued Sixth Straight Quarter of Double-Digit Gains - Insider Monkey
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent - Stock Titan
Jim Cramer Predicts Big Earnings for Abbott Laboratories (ABT): Libre Leads the Way! - Insider Monkey
Impressive Earnings May Not Tell The Whole Story For Abbott Laboratories (NYSE:ABT) - Yahoo Finance
Abbott’s rapid blood-based concussion test is off to the races - Fierce Biotech
The Zacks Analyst Blog Highlights GE Healthcare, Johnson & Johnson, Abbott and Boston Scientific - Yahoo
Judge throws out case against Abbott over preterm baby formulas - Chicago Tribune
One of Abbott's first federal baby formula lawsuits dismissed - Crain's Chicago Business
Abbott Beats Bellwether Formula MDL Trial in Federal Court Ruling - USA Herald
Judge throws out case against Abbott Laboratories over its preterm baby formula, days before trial was set to begin in Chicago - Yahoo
Positive Legal and Market Factors Justify Buy Rating for Abbott Laboratories - TipRanks
Judge Allows Testimony That Abbott, Mead Johnson Baby Formula Caused Disease - Insurance Journal
Winnetka crash: Raziyeh Sigary, Sediqeh Samadi identified as pedestrians killed at Church Road, Meadow Road; infant injured - ABC7 Chicago
Abbott (ABT) Launches Rapid Concussion Test with MotoAmerica - GuruFocus
Abbott Nutrition Reaches Deal With FDA To Reopen Baby Formula Plant Amid Shortage - Class Action Lawsuits
Abbott Laboratories Director Makes Significant Stock Sale! - TipRanks
Abbott Beats Bellwether In Formula MDL Ahead Of Trial - Law360
US judge allows testimony that Abbott and Mead Johnson preterm baby formula caused deadly disease - Reuters
Abbott Laboratories (ABT) Sees Stock Rise Following Favorable Court Ruling - GuruFocus
Abbott gains after upcoming baby formula case thrown out (ABT:NYSE) - Seeking Alpha
Abbott Laboratories First Quarter 2025 Earnings: EPS Misses Expectations - simplywall.st
Stroke Management Market Is Booming Worldwide | Abbott - openPR.com
Investors in Abbott Laboratories (NYSE:ABT) have seen notable returns of 52% over the past five years - Yahoo Finance
Abbott Laboratories Announces Executive Vice President’s Retirement - TipRanks
Abbott Laboratories (ABT): Among the Best Stocks to Buy During Recession - Insider Monkey
MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races - Yahoo Finance
Abbott Laboratories price tries to shake off negative pressureForecast today01-05-2025 - Economies.com
MotoAmerica: More On Abbott Blood Test for Rapid Concussion Evaluation On-Site - Roadracing World
Abbott Laboratories (ABT): Jim Cramer Calls It a ‘Tour de Force’ — Why He’s Still Amazed at This Stock - Yahoo Finance
Abbott Laboratories (ABT) Announces Results of Annual Shareholders Meeting - GuruFocus
Abbott (ABT) Integrates Libre CGM Data with Epic's Health Records - GuruFocus
Abbott signs deal with Epic for CGM data integration (ABT:NYSE) - Seeking Alpha
Abbott Integrates Libre CGM’s Data with Epic’s EHR System - Medical Product Outsourcing
Abbott (ABT) Teams Up with Epic for Advanced Health Data Integra - GuruFocus
Abbott integrates Libre CGM data into Epic EHR workflows - Drug Delivery Business
Abbott Partners With Epic to Transform Diabetes Care for 280M Patients | ABT Stock News - Stock Titan
Sevoflurane Market Overall Study Report 2025-2032 | Abbott Laboratories, Baxter, Piramal Pharma Solutions - openPR.com
A Look Into Abbott Laboratories Inc's Price Over Earnings - Benzinga
Abbott Laboratories (NYSE:ABT) Unveils Breakthrough Leadless Pacemaker Advances In New Clinical Trials - simplywall.st
3 Dividend Stocks to Buy and Hold for the Next Decade - Yahoo Finance
Abbott (ABT) Unveils Promising Results from Leadless Pacemaker S - GuruFocus
The Zacks Analyst Blog Highlights Abbott Laboratories, Boston Scientific and Medtronic - Yahoo Finance
Drug Eluting Stents Market Overall Study Report 2025-2032 | - openPR.com
Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price - Yahoo Finance
Abbott Laboratories Insiders Sold US$3.3m Of Shares Suggesting Hesitancy - simplywall.st
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.44%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):